Horizon Discovery Group plc announced that it has entered into an exclusive strategic partnership with Rutgers, The State University of New Jersey (US), to develop and commercialize a novel gene editing technology, known as base editing. The technology potentially has applications in the development of new cell therapies and will augment Horizon's research tools and services. Horizon will collaborate with Rutgers University to further develop the novel base editing platform from the laboratory of Dr. Shengkan Jin, associate professor of pharmacology at Rutgers Robert Wood Johnson Medical School. As part of the agreement, Horizon has made a non-material payment to Rutgers for an option to exclusively license the base editing technology for use in all therapeutic applications. As part of the collaboration, Horizon will also fund further research in base editing at Rutgers University while undertaking evaluation and proof of concept studies at Horizon.